Jennifer Littledike, PA
Medical · Stansbury Park, UTNPI 1063729481
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AbbVie at 36.4% of the total.
Across 207 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$266
- AstraZeneca$239
- Lilly USA, LLC$235
- Mylan Specialty L.p.$215
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$149
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,749100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 70 | $1,364 |
| Novo Nordisk | 18 | $266 |
| AstraZeneca | 16 | $239 |
| Lilly USA, LLC | 14 | $235 |
| Mylan Specialty L.p. | 11 | $215 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $149 |
| Pfizer | 9 | $135 |
| Medtronic | 6 | $112 |
| Astellas Pharma US Inc | 5 | $107 |
| Supernus Pharmaceuticals, Inc. | 4 | $88 |
| Boehringer Ingelheim | 5 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $76 |
| Bayer | 4 | $76 |
| Dexcom, Inc. | 1 | $76 |
| Lundbeck LLC | 3 | $53 |
| Alkermes, Inc. | 3 | $49 |
| Antares Pharma, Inc. | 3 | $41 |
| Organon | 3 | $40 |
| Merck | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Inspire Medical Systems, Inc. | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $32 |
| Eisai Inc. | 2 | $31 |
| Viatris Specialty LLC | 1 | $27 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Boston Scientific | 1 | $20 |
| Indivior Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Ardelyx, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
How this compares
$3,749 in reported general payments places this provider in the 80th percentile of 263 medical providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 51 | $54,332 |
| OzempicSemaglutide | 29 | $31,385 |
| LinzessLinaclotide | 32 | $25,419 |
| FarxigaDapagliflozin Propanediol | 22 | $14,970 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $12,258 |
| VascepaIcosapent Ethyl | 28 | $11,016 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $5,911 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,686 |
| Varenicline Tartrate | 14 | $4,562 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $3,368 |
| Duloxetine Hcl | 87 | $2,057 |
| Gabapentin | 133 | $1,683 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 61 | $1,323 |
| Buspirone Hcl | 80 | $1,319 |
| Hydroxyzine Hcl | 33 | $1,123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $235 | $54,33251 claims |
| Novo NordiskOzempic | $266 | $31,38529 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $239 | $27,22841 claims |
| AbbVieLinzess | $1,364 | $25,41932 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $76 | $4,68612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 263 medical providers in Utah.
Other medical in Stansbury Park
- Elisa WilcoxSalt Lake City$178K
- Val WarnerLayton$51K
- Viet leSalt Lake City$42K
- Carmelo DiazSalt Lake City$35K
- Shari CombeSalt Lake City$22K
- Kelly MikesellOgden$19K
- Jennifer CoombsSlc$12K
- Brandon HansenRiverton$10K
- Daniel CorryCedar City$10K
- Mark UdySt George$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.